Articles
| Open Access |
DOI: Clinical Cases Of Hepatitis-Associated Aplastic Anemia
Makhmudov Ravshan Barraevich , Bukhara State Medical Institute, Uzbekistan Safarova Gulnoz Avazkhonovna , Bukhara State Medical Institute, UzbekistanAbstract
The article presents two cases of hepatitis-associated aplastic anemia in the last year. The literature data on the new nosology are presented. The clinical picture, diagnosis and treatment are discussed. The questions of diagnosis and treatment that affect the prognosis are raised. Treatment preference should be given to allogeneic bone marrow transplantation, as it has better results than aggressive immunosuppressive therapy that is difficult for patients to tolerate.
Keywords
Hepatitis-associated aplastic anemia, immunosuppressive therapy
References
Kosterina A.V., Nazipova Z.M., Marapov D.I. The effectiveness of the use of immunosuppressive therapy and splenectomy in the treatment of patients with aplastic anemia on the example of the experience of the Department of Hematology of the RCH // Practical Medicine. - 2016. - No. 4 (96). - S. 68-72. [in russian]
Brown K.E., Tisdale J., Barrett A.J., et al. Hepatitis-associated aplastic anemia // N. Engl. J. Med. ― 1997. ― 336. ― P. 1059.
Osugi Y., Yagasaki H., Sako M., et al. Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia // Haematologica. ― 2007. ― 92. ― P. 1687.
Ohara A., Kojima S., Okamura J., et al. Evolution of myelodysplastic syndrome and acute myelogenous leukaemia in children with hepatitis-associated aplastic anaemia // Br. J. Haematol. ― 2002. ― 116. ― P. 151.
Савченко В.Г. Клинические рекомендации по лечению апластической анемии // Национальное гематологическое общество. ― 2014. ― С. 8-22.
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.